Successful Prophylactic Use of Recombinant Activated Factor VII (rFVIIa) in a Patient with Congenital FVII Deficiency and Inhibitors to FVII
Yükleniyor...
Dosyalar
Tarih
2012
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
WILEY
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Congenital factor VII (FVII) deficiency is a rare, autosomal recessive bleeding disorder. The clinical phenotypes range from asymptomatic condition to severe disease characterized by life-threatening bleedings [1]. Optimal replacement therapy for FVII deficiency consists of recombinant activated factor VII (rFVIIa) or plasma derived FVII (pdFVII) concentrates. Although rare, the formation of neutralizing antibodies to FVII is an important concern of replacement therapy in the treatment of FVII deficiency [1]. Herein, we report the clinical progress of a patient with severe FVII deficiency who developed inhibitors against FVII during treatment with rFVIIa.
Açıklama
Anahtar Kelimeler
Kaynak
HAEMOPHILIA
WoS Q Değeri
Q2
Scopus Q Değeri
Q1
Cilt
18
Sayı
1
Künye
Tokgöz, H., Çalışkan, U., Lavigne-Lissalde, G., Giansily-Blaizot., (2012). Successful Prophylactic Use of Recombinant Activated Factor VII (rFVIIa) in a Patient with Congenital FVII Deficiency and Inhibitors to FVII. Haemophilia, 18, e25-e27. DOI: 10.1111/j.1365-2516.2011.02668.x
